From September, Singapore mandates measles shots for helpers in homes with unvaccinated kids
SINGAPORE, June 11 — From September 1, all domestic helpers in Singapore working in homes with children under the age of seven who are not fully vaccinated against measles must themselves be immunised, the country's Ministry of Manpower (MOM) announced yesterday.
The move is aimed at safeguarding 'unvaccinated young children who are at higher risk of serious health complications from measles infections', said MOM, as reported by Channel News Asia (CNA).
Singapore has already recorded 10 measles infections in 2025 as of the week ending May 10, just one shy of the total 11 cases reported in all of 2024, according to the Ministry of Health.
Employers applying for or renewing work permits for migrant domestic workers (MDWs) must now declare:
Whether the domestic helper is already vaccinated or immune to measles
Whether all children under seven in the household are fully vaccinated
If unvaccinated, whether a vaccination appointment has been booked
Domestic helpers may be exempted if they are already immune — either through previous infection or past vaccination — or if all children under seven in the home have been fully immunised. Proof of immunity, such as vaccination records or serology test results, may be required.
Employers are advised to check their domestic helper's immunity status well before permit renewal. Households with immunocompromised members are also strongly encouraged to verify their helper's measles immunity or arrange for vaccination.
To meet the requirement, domestic helpers must receive two doses of the MMR (measles, mumps, and rubella) vaccine, spaced at least 28 days apart. The vaccine is available at private GP clinics, with the cost to be paid by employers.
MOM also warned against false declarations. 'If employers with children below seven years old are found with MDWs who are not immune against measles, their work pass privileges may be suspended until vaccination proof is submitted,' the ministry said.
Random checks and documentary audits will be conducted to ensure compliance.
While Singapore maintains high overall vaccination rates — over 95 per cent for the first MMR dose and 90 per cent for the second among resident two-year-olds — sporadic cases are expected, MOM said, citing the 'highly transmissible nature of the disease'.
The Communicable Diseases Agency (CDA) stressed that despite strong local immunity, 'the surge in measles cases globally and regionally continues to pose public health risks, particularly for those without measles immunity'.
Measles, which spreads through airborne droplets, has been part of Singapore's compulsory childhood immunisation schedule since 1985.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Measles 'out of control,' experts warn, as Alberta case counts surpass 1,000
Alberta's measles outbreaks have now eclipsed the 1,000-case mark and infectious disease specialists are warning the virus is "impossible to contain," given the current level of transmission. The province reported another 24 cases on Friday, including 14 in the north zone, nine in the south and one in the Edmonton zone. This brings the total confirmed cases since the outbreaks began in March to 1,020. "It is a very grim milestone," said Dr. Karina Top, a pediatric infectious disease physician at the Stollery Children's Hospital in Edmonton, which has been treating children with measles. "I'm very worried we're going to see more hospitalizations and some deaths soon because we know the death rate is about one to two per thousand. So it's likely that we're going to see that and that will be a very tragic day." Measles is highly contagious and can lead to serious complications including pneumonia, brain inflammation — which can trigger seizures, deafness and brain damage — as well as premature delivery. A premature baby who was born with measles died in Ontario recently. And another young child died of measles in that province last year. Doctors warn there are severe long-term consequences as well, including immune system impacts and a degenerative neurological condition that occurs seven to ten years after an initial measles infection. It is rare but nearly always fatal. 'Out of control' Alberta's case count has more than doubled in the last month. On May 20, a total of 486 cases had been confirmed. "This is out of control," said Top. The hardest hit areas are the south, central and north zones, where there are some very low vaccination rates among young children. Case counts have been rising quickly in the north zone, which has now topped 200 cases. The south zone has confirmed 681 cases and the central zone has 105. And health officials are warning the virus is more widespread in those areas than case counts reflect. "Due to the number of people in these areas who may not be immune to measles, it's likely that some cases are going undetected or unreported," the Alberta government's measles web page states. "I think we really need to be doing everything we can to engage with those communities that are affected and community leaders to see how best we can work with them to try to get people vaccinated to help contain this infection," said Top. "And [we need to] get everyone else up to date so that if there are other cases introduced in Edmonton, Calgary or elsewhere in the province, it can be contained more quickly." University of Calgary infectious disease physician Dr. Dan Gregson is also worried about Alberta's surging measles cases. "This transmission is just out of the box. It's impossible to contain at the present time," he said. "The risk, right now, of your child getting measles in Alberta if they're not immunized is pretty high." Gregson is urging parents who have opted not to immunize their children to rethink that decision. "If you had made a decision not to vaccinate because measles was not circulating, that's no longer true. We don't have herd immunity. There's measles circulating in the community. And the best way to prevent your child from having a complication would be to get them vaccinated," he said. The vast majority of Alberta's measles cases are among the unimmunized. The most recent data shows 85 Albertans have been hospitalized due to this year's outbreaks, including 14 who have ended up in intensive care. "Most of these hospitalizations are due to patients having pneumonia — they're short of breath, they have to wear oxygen. Some of them are due to brain inflammation. [It's] not a pleasant thing for the parents or the child to have to go through," said Gregson. In Edmonton, where the Stollery Children's Hospital is treating the sickest patients from northern Alberta, Top said the outbreaks are taking a toll. "It is distressing as a pediatrician to see children that are sick from a disease that is completely vaccine preventable." According to provincial data, as of Friday there was one Albertan in ICU due to measles. No deaths have been reported.
Yahoo
3 hours ago
- Yahoo
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with placebo1 Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the first 4 weeks, compared to placebo1 The SUNRISE trial met all key secondary efficacy endpoints with improvements seen as early as day 1 and sustained through week 121 VALBY, Denmark, June 21, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the full results from the SUNRISE trial, a randomized, placebo-controlled trial designed to evaluate the efficacy and safety of eptinezumab versus placebo in a predominantly Asian population with chronic migraine. The study was presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.1 "Various treatments are recommended for patients with migraine in Asia, however utilization and adherence to migraine-specific treatment is relatively low. Access to effective treatments remains a significant unmet medical need for migraine prevention in Asia" said Johan Luthman, EVP and Head of R&D at Lundbeck. "The data from SUNRISE is consistent with previous results across diverse populations and will be pivotal for our efforts to expand access to eptinezumab for patients in Asia suffering with severe migraine." The double-blind, pivotal, SUNRISE trial (n=983) met all key primary and secondary endpoints, with eptinezumab demonstrating greater reductions in migraine frequency, the proportion of migraine attacks with severe pain, and disease burden, compared to placebo.1 "The SUNRISE trial marks a significant step forward in the mission to make migraine-specific preventive treatments more globally accessible, ensuring that patients with severe migraine receive the care they need" said Dr Patricia Pozo-Rosich, Head of Section of the Neurology Department, Director of Headache and Craniofacial Pain Clinical Unit and the Migraine Adaptive Brain Center at the Vall d'Hebron University Hospital in Barcelona, and principal investigator in the SUNRISE trial. In the SUNRISE trial, patients receiving eptinezumab experienced significantly fewer monthly migraine days (MMDs), with eptinezumab offering a -7.5 (300 mg) and -7.2 (100 mg) reduction in MMDs from week 1 through to 12, versus -4.8 with placebo (baseline MMD = 17, p<0.0001 for both 300 mg and 100 mg vs placebo).1 Amongst other parameters, patients receiving eptinezumab (300 mg or 100 mg) were four times more likely to achieve a reduction of ≥75% in the number of migraine days per month, compared to placebo within the first 4 weeks (p<0.0001).1 In the same study, eptinezumab also demonstrated a rapid onset of preventive efficacy, where more participants reported being free of migraine as early as day 1 after receiving eptinezumab treatment compared to placebo (p<0.002 for 300 mg dose; p<0.01 for 100 mg dose). This clinical efficacy was also reflected in patient reported outcomes where patients reported clinically meaningful improvements which were greater with eptinezumab than with placebo.1 Finally, the safety profile of eptinezumab was generally similar to placebo, previous trials, and to the current labelled safety information in the United States prescribing information and EU Summary of Product Characteristics, with the most common treatment-emergent adverse events being COVID-19 and nasopharyngitis.1 Based on the SUNRISE results, Lundbeck has initiated discussions with relevant regulatory authorities with the aim of making eptinezumab available for people suffering from migraine across Asia. About migraine Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound. Not only is headache painful, but migraine also imposes both a social and financial burden. Migraine has a profound impact on patient functioning including relationships with family/friends, leisure activities, household production and worker productivity. Migraine is one of the most prevalent neurological diseases for which medical treatment is sought, and worldwide, is considered the leading cause of disability for people under the age of 50 and the 2nd leading cause of disability worldwide.3,4 Repeated headache attacks, and often the constant fear of the next one, damage family life, social life and work life. Furthermore, frequent use of acute migraine treatments may leave patients experiencing, or at risk of developing, medication overuse headache. Despite equally high prevalence of migraine in Asia as compared western countries, significant unmet needs remain in terms of sufficient and appropriate diagnosis, and better management and therapies for treatment of migraine in East Asia.5 In China, an estimated 14.3% of adults are living with migraine. From this population, approximately 52.9% will visit hospitals and only 13.8% of them will be diagnosed with migraine.6 About the SUNRISE trial SUNRISE (NCT04921384) is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled phase III trial, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.2 The study was conducted to support marketing authorization across Asia. Chronic migraine was defined as migraine occurring on ≥8 days per month and headache occurring on >14 days. Participants were randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo. The double-blind, placebo-controlled treatment period was followed by an extension period where all participants received active treatment to further assess the safety and tolerability of eptinezumab. The total trial duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Extension Period (12 weeks), and a Safety Follow-up Period (8 weeks).1 Participants in Japan completing the SUNRISE trial were offered to continue in the SUNSET trial (NCT05064371) which consisted of an open-label eptinezumab treatment of 60 weeks (five infusions), and a Safety Follow-up Period (8 weeks). The SUNRISE was initiated in May 2021 and was conducted in Mainland China, Georgia, Japan, Poland, Slovakia, South Korea, Spain and Taiwan. In the trial, 983 participants were randomized to receive eptinezumab 100 mg or 300 mg or placebo by intravenous (IV) infusion.2 About Vyepti® (eptinezumab) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III clinical trials (PROMISE-1 in episodic migraine7 and PROMISE-2 in chronic migraine8), where eptinezumab met its primary endpoint of decrease in MMDs over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of eptinezumab as early as day 1 post-infusion. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions. Vyepti® (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in more than 30 markets worldwide. Contacts Marie Petterson Jens Høyer Head of Media Relations, Corp. Communication Vice President, Head of Investor Relations MEEP@ JSHR@ +45 29 82 21 82 +45 30 83 45 01Palle Holm OlesenVice President, Investor RelationsPALO@ 30 83 24 26 About H. Lundbeck A/S Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site and connect with us via LinkedIn. References: Yu S, ePresentation at EAN Congress 2025 H. Lundbeck A/S. Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise). NCT04921384 Steiner TJ, Stovner LJ, Vos T. et al. J Headache Pain 2018; 19: 17. Leonardi M, Steiner TJ, Scher AT, Lipton RB. J Headache Pain. 2005; 6(6): 429– 440. Takeshima, T, et al. J Headache Pain 2019; 20, 111 Guidelines for the diagnosis and treatment of migraine in China (2022 edition). Chinese Journal of Pain Medicine 2022, 28 (12) Ashina M, et al. Cephalalgia. 2020 Mar;40(3):241-254. Lipton RB, et al. Neurology. 2020 Mar 31;94(13):e1365-e1377. CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@ This information was brought to you by Cision The following files are available for download: EAN 2025 Press Release SUNRISE_Final View original content:
American Military News
6 hours ago
- American Military News
Videos/Pics: Iran's ‘terrorist tyrants' strike Israeli hospital, Israel vows revenge
Israeli Prime Minister Benjamin Netanyahu issued a major warning to Iran on Thursday after Iran's 'terrorist tyrants' launched missiles and struck a hospital in Israel amid the increased conflict between the two countries following Israel's preemptive strikes against Iran's nuclear and ballistic missile programs last week. In a translated post on X, formerly Twitter, Netanyahu wrote, 'This morning, Iran's terrorist tyrants launched missiles at Soroka Hospital in Beersheba and at a civilian population in the center of the country. We will exact the full price from the tyrants in Tehran.' Trey Yingst, chief foreign correspondent for Fox News, reported that Israel's Soroka Hospital, which he confirmed was the largest hospital in the southern region of Israel, sustained 'significant damage' after taking a 'direct hit from an Iranian ballistic missile.' A video shared by the Israeli government shows people running in the aftermath of the Iranian missile strike against the Soroka Hospital. The Israeli government noted that the ballistic missile hit a 'major medical center,' adding, 'We will not stand by. We will continue doing what must be done to defend our people.' The Iranian regime targeted Soroka Hospital in Beersheba with a ballistic missile—hitting a major medical center. We will not stand by. We will continue doing what must be done to defend our people. — Israel ישראל (@Israel) June 19, 2025 In a post on social media, Israeli President Isaac Herzog shared pictures of the remains of the Soroka Hospital. The Israeli president explained that he visited the hospital on Thursday morning and was met by doctors, nurses, and patients. READ MORE: Videos: 60 Israeli jets target Iran's ballistic missiles 'We stood together and looked at the destruction and devastation caused by an Iranian missile fired indiscriminately with the sole intention to take innocent lives in a hospital,' Herzog stated. 'This is a war crime!' I arrived at Soroka Hospital in Be'er Sheva this morning, to be greeted by Director of the hospital, Prof. Shlomi Kodesh, along with doctors, nurses, and patients, Jews and Muslims, from all walks of life from across the beautiful Negev. We stood together and looked at the… — יצחק הרצוג Isaac Herzog (@Isaac_Herzog) June 19, 2025 The Israeli Ministry of Health confirmed that 271 people were hospitalized following Iran's overnight attacks. The Israeli Ministry of Health also confirmed that at least 71 people were hospitalized due to the missile strike against the Soroka Hospital. Speaking from the site of the hospital attack on Thursday, Netanyahu said, 'We accurately hit nuclear targets and missile targets, and they hit a hospital, where people can't even get up and run away. They are harming not far from here – there is a children's and infants' ward here. That's the whole difference in a democracy that acts according to the law to save itself from these murderers and against these murderers who want to destroy each and every one of us. Every single one of us. Down to the last one of us. I think that says it all.' אני כאן בבית החולים סורוקה בבאר שבע יחד עם שר הבריאות וסגן השר אלמוג כהן, איש הדרום, ולא בפעם הראשונה עם מנהל בית החולים סורוקה. אנחנו רואים כאן את כל ההבדל. אנחנו פוגעים במדויק במטרות גרעין ומטרות טילים, והם פוגעים בבית חולים, שאנשים לא יכולים לקום ולברוח אפילו. הם פוגעים לא… — Benjamin Netanyahu – בנימין נתניהו (@netanyahu) June 19, 2025
